Logo

PSNL

Personalis, Inc.

PSNL

Personalis, Inc. • NASDAQ
$10.73 ▲ 0.09% (+0.01)
Market Cap $952.82 M
52w High $11.40
52w Low $2.83
Dividend Yield 0%
P/E -12.93
Volume 460.44K
Outstanding Shares 88.80M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $14.495M ▼ $25.205M ▼ $-21.652M ▼ -149.376% ▼ $-0.24 ▼ $-19.183M ▼
Q2-2025 $17.203M ▼ $26.56M ▲ $-20.056M ▼ -116.584% ▼ $-0.23 ▼ $-17.475M ▼
Q1-2025 $20.605M ▲ $24.903M ▲ $-15.75M ▲ -76.438% ▲ $-0.18 ▲ $-13.128M ▲
Q4-2024 $16.8M ▼ $22.662M ▼ $-16.425M ▲ -97.768% ▲ $-0.23 ▲ $-13.879M ▲
Q3-2024 $25.709M $23.127M $-39.089M -152.044% $-0.64 $-36.321M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $150.515M ▼ $242.839M ▼ $71.424M ▲ $171.415M ▼
Q2-2025 $173.232M ▼ $258.68M ▼ $67.851M ▲ $190.829M ▼
Q1-2025 $185.688M ▲ $273.308M ▲ $65.963M ▼ $207.345M ▲
Q4-2024 $185.009M ▲ $270.268M ▲ $67.311M ▼ $202.957M ▲
Q3-2024 $143.651M $239.887M $73.126M $166.761M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-21.652M ▼ $-21.804M ▼ $18.724M ▲ $-317K ▲ $-3.401M ▲ $-23.43M ▼
Q2-2025 $-20.056M ▼ $-12.935M ▲ $-4.371M ▲ $-327K ▼ $-17.627M ▲ $-13.225M ▲
Q1-2025 $-15.75M ▲ $-17.961M ▼ $-22.542M ▲ $20.087M ▼ $-20.414M ▼ $-20.472M ▼
Q4-2024 $-16.425M ▲ $-7.796M ▼ $-26.183M ▲ $49.601M ▼ $15.615M ▼ $-9.042M ▼
Q3-2024 $-39.089M $-6.198M $-28.18M $62.426M $28.053M $-6.445M

Five-Year Company Overview

Income Statement

Income Statement Personalis is still very much in the “building” phase. Revenue has been fairly flat over the last several years rather than showing a clear growth ramp, which is a concern for a company investing heavily in a new platform. Gross profit is positive but modest, and operating losses remain large, meaning the business is far from covering its cost base. The good news is that losses appear to be easing somewhat in the most recent year after peaking earlier, but the company is still firmly unprofitable with meaningful per-share losses. The key financial question is whether revenue can start to scale fast enough to absorb its fixed R&D and commercial costs.

Balance Sheet

Balance Sheet The balance sheet shows a company that still has a solid asset base and meaningful cash, but it has been drawn down compared with earlier years. Equity is positive, which means assets still comfortably exceed liabilities, though the cushion is thinner than at the company’s peak. Debt exists but is not dominant relative to total capital. Overall, the balance sheet gives Personalis some room to keep investing, but not unlimited runway, so future funding needs and dilution risk remain important watch-points if losses persist.

Cash Flow

Cash Flow Cash flow from operations has been consistently negative, reflecting the ongoing losses and heavy spending on research, commercialization, and infrastructure. Free cash flow has also been clearly negative every year, though the cash burn has recently narrowed as capital spending has come down from its earlier peak. The company has essentially shifted from a phase of heavy investment in equipment and build-out to a more controlled spending pattern, but it still depends on its cash reserves and external financing to fund operations until the business becomes self-sustaining.

Competitive Edge

Competitive Edge Personalis operates in a highly competitive and fast-moving corner of oncology diagnostics, but it has carved out a differentiated position. Its NeXT Platform offers unusually comprehensive genomic profiling, going far beyond narrow gene panels and giving drug developers and clinicians a richer picture of the tumor and immune environment. The NeXT Personal minimal residual disease test competes in a crowded MRD space but leans on very high sensitivity and a personalized, tumor-informed design. Proprietary analytics, complex bioinformatics, and the Tempus AI partnership together create meaningful barriers to entry and extend its commercial reach, especially to community oncologists. That said, the company still faces intense competition from larger, better-funded players and must prove it can translate its technology edge into broad clinical adoption and durable revenue.

Innovation and R&D

Innovation and R&D Innovation is clearly the core of Personalis’s story. The company has built a full-stack genomics platform—whole exome and transcriptome sequencing plus advanced algorithms—that supports multiple products for both biopharma research and clinical care. Its R&D focus is now shifting from just building the technology to broadening its real-world use: expanding NeXT Personal into additional cancer types, deepening evidence through trials like VICTORI in colorectal cancer, and developing composite biomarkers that can better predict treatment response. Success in securing reimbursement, especially from Medicare, will be critical for turning this R&D investment into sustainable revenue. Overall, Personalis is acting like a high-science, platform-first company, with R&D as its primary strategic lever, but the payoff is still ahead rather than fully visible in current financials.

Summary

Personalis is a science-driven precision oncology company with promising technology but an early-stage financial profile. On the positive side, it has a clearly differentiated platform, strong scientific credentials, and meaningful partnerships that support its competitive position. On the risk side, revenue has not yet scaled to match its cost structure, losses remain substantial, cash burn is ongoing, and future funding needs are a key uncertainty. The company’s long-term outcome will likely hinge on a few critical execution points: gaining broad reimbursement for its MRD tests, converting its Tempus collaboration into real test volume, and demonstrating that its comprehensive approach leads to better clinical outcomes and durable customer demand.

NEWS

November 18, 2025 · 4:01 PM UTC

Personalis to Participate in the Piper Sandler 37th Annual Healthcare Conference

Read more

November 10, 2025 · 9:00 AM UTC

Personalis Announces Medicare Coverage for Ultrasensitive MRD Test in Breast Cancer

Read more

November 4, 2025 · 4:01 PM UTC

Personalis Reports Third Quarter 2025 Financial Results

Read more

October 21, 2025 · 4:01 PM UTC

Personalis to Announce Third Quarter 2025 Financial Results

Read more

October 16, 2025 · 9:00 AM UTC

Personalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD Testing

Read more